Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  T. Welte,et al.  Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease , 2011, PharmacoEconomics.

[3]  P. Calverley,et al.  A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease , 2007, PharmacoEconomics.

[4]  J. Søgaard,et al.  The Danish Approach to Standards For Economic Evaluation Methodologies , 1997, PharmacoEconomics.

[5]  Paul Jones,et al.  COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population , 2011, BMC public health.

[6]  V. Kinnula,et al.  The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[7]  A. Gulsvik,et al.  Excessive costs of COPD in ever-smokers. A longitudinal community study. , 2011, Respiratory medicine.

[8]  J. Vestbo,et al.  Prevalence of COPD in Copenhagen. , 2011, Respiratory medicine.

[9]  K. Larsson,et al.  COPD health care in Sweden - A study in primary and secondary care. , 2010, Respiratory medicine.

[10]  D. Suh,et al.  Association between incidence of acute exacerbation and medication therapy in patients with COPD , 2010, Current medical research and opinion.

[11]  A. Gulsvik,et al.  Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general population , 2010, The clinical respiratory journal.

[12]  T. Welte,et al.  Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[13]  A. Buist,et al.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study , 2009, European Respiratory Journal.

[14]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[15]  P. Jones,et al.  Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD , 2008, Thorax.

[16]  Liam Ck.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008 .

[17]  K. Overvad,et al.  The Prevalence of Chronic Obstructive Pulmonary Disease among Danes Aged 45–84 Years: Population-based Study , 2008, COPD.

[18]  J. Maurer.  Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2008 .

[19]  D. Mannino,et al.  International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.

[20]  J. Dollerup,et al.  The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls. , 2007, Respiratory medicine.

[21]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[22]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[23]  A. Lindberg,et al.  Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2006, Respiratory medicine.

[24]  A. Gulsvik,et al.  Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study , 2005, Thorax.

[25]  B. Lundbäck,et al.  Chronic Obstructive Pulmonary Disease in Finland: Prevalence and Risk Factors , 2005, COPD.

[26]  C. Jenkins,et al.  The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.

[27]  J. V. van Noord,et al.  One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease , 2004, European Respiratory Journal.

[28]  K Larsson,et al.  Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.

[29]  T. Hujanen.  Terveydenhuollon yksikkökustannukset Suomessa vuonna 2001 , 2003 .

[30]  S. Borg,et al.  Costs of COPD in Sweden according to disease severity. , 2007, Chest.

[31]  K. Stavem,et al.  [Coding of diagnoses in chronic obstructive pulmonary disease--economic consequences]. , 2002, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[32]  E. Rönmark,et al.  The costs of exacerbations in chronic obstructive pulmonary disease (COPD). , 2002, Respiratory medicine.

[33]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.